IN8BIO, Inc. INAB
IN8BIO, Inc. (Nasdaq: INAB) is an oncology drug developer. Its lead program, INB-100, is in Phase 1 for high-risk leukemias (AML) undergoing haploidentical stem cell transplantation. Its next catalyst on record is INB-100: Complete treatment of all expansion-cohort patients and present clinical update (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: INB-100 — Complete treatment of all expansion-cohort patients and present clinical update (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INB-400 (DeltEx DRI, autologous) | newly diagnosed glioblastoma | cell therapy | Phase 2 |
| INB-100 (DeltEx Allo) | high-risk leukemias / AML with HSCT | cell therapy | Phase 1 |
| INB-200 (DeltEx DRI, investigator-sponsored) | newly diagnosed glioblastoma | cell therapy | Phase 1 |
| INB-619 (CD19 gamma-delta T cell engager) | B cell-driven autoimmune diseases (e.g., SLE) | antibody | Pre-clinical |
| INB-300 (nsCAR gamma-delta T cell) | solid and liquid tumors | cell therapy | Pre-clinical |
| INB-500 (iPSC-derived gamma-delta T cells) | cancer | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.